In conclusion, these results might indicate that the LUCAT1/NCL/MYC axis might be a potential prognostic marker and therapeutic target in CRC, potentially providing new insight into CRC progression and treatment. The gene discussed is NUCLEOLIN; the disease is colorectal carcinoma.